GENEART Receives a Grant for the Targeted Design of Vaccine

Tag : avian influenza

Aside from optimizing the gene sequences using the proprietaryGENEART GeneOptimizer(R) technology for the efficient production ofthe vaccine, GENEART will also use an iterative process to optimizethe design of the desired protein antigen. The objective is theproduction of an antigen that shows the optimal crossbeta structurefor the desired immune response.
Professor Dr. Ralf Wagner, CEO of the GENEART AG, comments: "Thisproject supports our activities in the area of targeted proteindesign. Today, we are the global leaders in the design ofcustomized genes. In the medium term, we plan to extend ourbusiness and leadership role by offering the design of customizedproteins as well. This does not only complement our currentservices but also adds additional value for our customers, forexample in the pharmaceutical industry."
Further scientific information is available under www.crossbeta.com
Legal Information
This document may contain estimates, prognoses and opinions aboutcompany plans and objectives, products or services, future results,opinions about these results or opinions leading up to theseresults. All these projections into the future are subject to risk,uncertainty and unforeseeable change outside the control of theGENEART Group. Many factors may lead to actual results, whichconsiderably deviate from the given projections for these results.
About GENEART AG
In 2000, GENEART entered the gene synthesis market and has sincebecome the global market leader. Today, the company is one of theleading specialists in the Synthetic Biology field. Experts atGENEART provide key technologies for the development and productionof new therapeutics and vaccines. Customers also take advantage ofGENEART services to customize enzyme attributes, such as theattributes of enzymes used as detergent additives, and to constructbacteria, which produce complex biopolymers or break down polymers,such as synthetics, petroleum components, etc. Our production andservice spectrum spans a wide range, from the production ofsynthetic genes according to DIN EN ISO 9001-2000, to the creationof gene libraries in the combinatorial biology, to the developmentand production of DNA-based biologically active substances. TheGENEART AG in Regensburg (Germany) and the subsidiary GENEART Inc.in Toronto (Canada) employ more than 190 people. Since May 2006,GENEART is listed on the German Stock Exchange.
About Crossbeta Biosciences BV
Crossbeta Biosciences is a spin-off biotechnology company of theUniversity Medical Center Utrecht and the University of Utrecht,the Netherlands. Crossbeta Biosciences offers innovative solutionsfor vaccine adjuvation and develops a drug discovery platform toprovide dedicated solutions for the detection and treatment ofdiseases that are caused by misfolded proteins. A key discovery atCrossbeta Biosciences was the recognition of a non-native proteinfold, the crossbeta structure, as an immunogenic entity that isable to induce a desired immune response when used as a vaccine,and that should be removed in order to prevent unwanted immuneresponses inflicted by for example aggregates in biologicals. InJune 2008, Crossbeta Biosciences moved from the UMC Utrechtlaboratories to its own facilities at the campus of the Universityof Utrecht. Today's crew of nine employees is about to be expandedto twenty plus for increasing our R&D activities in vaccinedevelopment and drug discovery platform development.
http://hugin.info/136633/R/1234704/263036.pdf
Copyright Copyright Hugin AS 2008. All rights reserved.
SOURCE: Geneart AG

Source: MARKET WIRE
More News in this Category